Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of BioMarin Pharmaceutical („BioMarin“ or the
„Company“) (NASDAQ: BMRN) resulting from allegations that BioMarin might have issued misleading information to the investing public.

If you purchased BioMarin securities, and/or would like to discuss your